Trials / Terminated
TerminatedNCT04292912
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
Phase I, Open-Label, Multi-Center Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2798745 After 28 Day Repeat Oral Administration to Adults With Diabetic Macular Edema
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study will be composed of 3 periods for all participants: Screening, 28-day Treatment period, and Follow-up visit (approximately 28 days after the final dose).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK2798745 | GSK2798745 will be administered. |
Timeline
- Start date
- 2020-09-07
- Primary completion
- 2022-04-11
- Completion
- 2022-04-11
- First posted
- 2020-03-03
- Last updated
- 2024-11-08
- Results posted
- 2024-11-08
Locations
11 sites across 3 countries: United States, Australia, New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04292912. Inclusion in this directory is not an endorsement.